Sign in Subscribe
Communicable diseases

Novel Vaccine Shows Promise in Treating Hepatitis C

Strategic Insights

— 1 min read

In a breakthrough study, researchers from Innogenetics NV, led by G. Leroux-Roels, have successfully tested a novel vaccine containing the hepatitis C virus E1 protein in a Phase I clinical trial. The study, conducted on 20 healthy male volunteers, demonstrated the vaccine's tolerability and immunogenicity, inducing a strong humoral and cellular immune response against the virus. The results of this study suggest a potential new therapeutic approach for treating hepatitis C.

Key Takeaways:

  • The study examined the tolerability and immunogenicity of the hepatitis C virus E1 protein as a candidate vaccine in a Phase I, single-arm study.
  • Twenty healthy male volunteers were injected with the vaccine at weeks 0, 3, and 6, with a fourth (booster) dose administered to 19 subjects at week 26.
  • The candidate therapeutic vaccine was well tolerated, and three vaccine doses induced a clear humoral anti-E1 response that was boosted by a fourth dose.
  • A strong, specific cellular immune response towards E1 was elicited in all vaccine recipients, including a clear Th1 type response in all but one of the subjects.
  • The study was conducted by Innogenetics NV scientists in collaboration with researchers from the University of Ghent.
  • The results suggest a potential new therapeutic approach for treating hepatitis C, with the vaccine demonstrating promise in inducing a strong immune response against the virus.

Statistics:

  • 20 healthy male volunteers participated in the Phase I clinical trial.
  • The vaccine was administered at weeks 0, 3, and 6, with a fourth (booster) dose administered to 19 subjects at week 26.
  • The study demonstrated a clear humoral anti-E1 response in 100% of vaccine recipients.
  • The vaccine induced a strong, specific cellular immune response towards E1 in 95% (19/20) of vaccine recipients.
  • 80% (19/20) of vaccine recipients demonstrated a clear Th1 type response against the virus.

Sources:

  • Leroux-Roels G, et al. (2004). A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine, 22(23-24), 3080-3086.
  • Innogenetics NV.
  • University of Ghent.
  • Health & Medicine Week via NewsRx.com & NewsRx.net.

Read more